The link between the loss of ARID1A and MSI and TMB, together with PD-L1 expression, TILs and systemic inflammatory markers [46–48] increases its clinical and prognostic relevance as a marker for screening and therapeutic response to targeted therapy and immune checkpoint inhibitors in gastric cancer. The gene discussed is ARID1A; the disease is gastric cancer.